New injection shows promise for kidney disease in early trial
NCT ID NCT07289763
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tests an experimental drug called SHR-2173 in 75 adults with primary membranous nephropathy, a kidney condition that can lead to kidney failure. The drug is given as an injection over several doses. Researchers are checking if it is safe and can help control the disease by reducing protein in the urine and improving kidney function.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SHR-2173 injection
What this could lead to
If successful, this could lead to a new treatment option that helps control primary membranous nephropathy and reduce kidney damage.
What could go wrong
This is an early Phase 2 trial with only 75 participants, so results may not apply to everyone. The drug may cause side effects or fail to improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY MEMBRANOUS NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
General hospital of eastern theater command
RECRUITINGNanjing, Jiangsu, 210002, China
Contact
Contact